Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1998 Nov;63(5):1341–1351. doi: 10.1086/302099

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

P N Tonin 1, A M Mes-Masson 1, P A Futreal 1, K Morgan 1, M Mahon 1, W D Foulkes 1, D E Cole 1, D Provencher 1, P Ghadirian 1, S A Narod 1
PMCID: PMC1377544  PMID: 9792861

Abstract

We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer and breast/ovarian cancer families from Quebec. To identify founder effects, we examined independently ascertained French Canadian cancer families for the distribution of these eight mutations. Mutations were found in 41 of 97 families. Six of eight mutations were observed at least twice. The BRCA1 C4446T mutation was the most common mutation found, followed by the BRCA2 8765delAG mutation. Together, these mutations were found in 28 of 41 families identified to have a mutation. The odds of detection of any of the four BRCA1 mutations was 18.7x greater if one or more cases of ovarian cancer were also present in the family. The odds of detection of any of the four BRCA2 mutations was 5.3x greater if there were at least five cases of breast cancer in the family. Interestingly, the presence of a breast cancer case <36 years of age was strongly predictive of the presence of any of the eight mutations screened. Carriers of the same mutation, from different families, shared similar haplotypes, indicating that the mutant alleles were likely to be identical by descent for a mutation in the founder population. The identification of common BRCA1 and BRCA2 mutations will facilitate carrier detection in French Canadian breast cancer and breast/ovarian cancer families.

Full Text

The Full Text of this article is available as a PDF (426.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman D. B., Costalas J., Schultz D. C., Grana G., Daly M., Godwin A. K. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res. 1996 Aug 1;56(15):3409–3414. [PubMed] [Google Scholar]
  2. Berman D. B., Wagner-Costalas J., Schultz D. C., Lynch H. T., Daly M., Godwin A. K. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet. 1996 Jun;58(6):1166–1176. [PMC free article] [PubMed] [Google Scholar]
  3. Bouchard G., Laberge C., Scriver C. R. Reproduction demographique et transmission genetique dans le nord-est de la province de Quebec (18e-20e siecles). Eur J Popul. 1988 Sep;4(1):39–67. doi: 10.1007/BF01797106. [DOI] [PubMed] [Google Scholar]
  4. Brais B., Xie Y. G., Sanson M., Morgan K., Weissenbach J., Korczyn A. D., Blumen S. C., Fardeau M., Tomé F. M., Bouchard J. P. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet. 1995 Mar;4(3):429–434. doi: 10.1093/hmg/4.3.429. [DOI] [PubMed] [Google Scholar]
  5. Casaubon L. K., Melanson M., Lopes-Cendes I., Marineau C., Andermann E., Andermann F., Weissenbach J., Prévost C., Bouchard J. P., Mathieu J. The gene responsible for a severe form of peripheral neuropathy and agenesis of the corpus callosum maps to chromosome 15q. Am J Hum Genet. 1996 Jan;58(1):28–34. [PMC free article] [PubMed] [Google Scholar]
  6. Couch F. J., Rommens J. M., Neuhausen S. L., Bélanger C., Dumont M., Abel K., Bell R., Berry S., Bogden R., Cannon-Albright L. Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics. 1996 Aug 15;36(1):86–99. doi: 10.1006/geno.1996.0428. [DOI] [PubMed] [Google Scholar]
  7. Davignon J., Roy M. Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a "founder effect". Am J Cardiol. 1993 Sep 30;72(10):6D–10D. doi: 10.1016/0002-9149(93)90003-u. [DOI] [PubMed] [Google Scholar]
  8. De Braekeleer M., Dao T. N. Founder effect in beta-thalassaemia in Portneuf, Québec. Nouv Rev Fr Hematol. 1993 Aug;35(4):447–450. [PubMed] [Google Scholar]
  9. Durocher F., Tonin P., Shattuck-Eidens D., Skolnick M., Narod S. A., Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet. 1996 Oct;33(10):814–819. doi: 10.1136/jmg.33.10.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. FitzGerald M. G., MacDonald D. J., Krainer M., Hoover I., O'Neil E., Unsal H., Silva-Arrieto S., Finkelstein D. M., Beer-Romero P., Englert C. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996 Jan 18;334(3):143–149. doi: 10.1056/NEJM199601183340302. [DOI] [PubMed] [Google Scholar]
  11. Friedman L. S., Szabo C. I., Ostermeyer E. A., Dowd P., Butler L., Park T., Lee M. K., Goode E. L., Rowell S. E., King M. C. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995 Dec;57(6):1284–1297. [PMC free article] [PubMed] [Google Scholar]
  12. Gayther S. A., Harrington P., Russell P., Kharkevich G., Garkavtseva R. F., Ponder B. A. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet. 1997 May;60(5):1239–1242. [PMC free article] [PubMed] [Google Scholar]
  13. Gayther S. A., Warren W., Mazoyer S., Russell P. A., Harrington P. A., Chiano M., Seal S., Hamoudi R., van Rensburg E. J., Dunning A. M. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995 Dec;11(4):428–433. doi: 10.1038/ng1295-428. [DOI] [PubMed] [Google Scholar]
  14. Heyer E., Tremblay M. Variability of the genetic contribution of Quebec population founders associated to some deleterious genes. Am J Hum Genet. 1995 Apr;56(4):970–978. [PMC free article] [PubMed] [Google Scholar]
  15. Hogervorst F. B., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G., Vasen H. F., Meijers-Heijboer H. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995 Jun;10(2):208–212. doi: 10.1038/ng0695-208. [DOI] [PubMed] [Google Scholar]
  16. Håkansson S., Johannsson O., Johansson U., Sellberg G., Loman N., Gerdes A. M., Holmberg E., Dahl N., Pandis N., Kristoffersson U. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet. 1997 May;60(5):1068–1078. [PMC free article] [PubMed] [Google Scholar]
  17. Johannesdottir G., Gudmundsson J., Bergthorsson J. T., Arason A., Agnarsson B. A., Eiriksdottir G., Johannsson O. T., Borg A., Ingvarsson S., Easton D. F. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996 Aug 15;56(16):3663–3665. [PubMed] [Google Scholar]
  18. Johannsson O., Ostermeyer E. A., Håkansson S., Friedman L. S., Johansson U., Sellberg G., Brøndum-Nielsen K., Sele V., Olsson H., King M. C. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet. 1996 Mar;58(3):441–450. [PMC free article] [PubMed] [Google Scholar]
  19. Labuda D., Zietkiewicz E., Labuda M. The genetic clock and the age of the founder effect in growing populations: a lesson from French Canadians and Ashkenazim. Am J Hum Genet. 1997 Sep;61(3):768–771. [PMC free article] [PubMed] [Google Scholar]
  20. Labuda M., Labuda D., Korab-Laskowska M., Cole D. E., Zietkiewicz E., Weissenbach J., Popowska E., Pronicka E., Root A. W., Glorieux F. H. Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am J Hum Genet. 1996 Sep;59(3):633–643. [PMC free article] [PubMed] [Google Scholar]
  21. Levy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., Lishinsky E., Shohat M., Weber B. L., Beller U., Lahad A. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  22. Mazoyer S., Dunning A. M., Serova O., Dearden J., Puget N., Healey C. S., Gayther S. A., Mangion J., Stratton M. R., Lynch H. T. A polymorphic stop codon in BRCA2. Nat Genet. 1996 Nov;14(3):253–254. doi: 10.1038/ng1196-253. [DOI] [PubMed] [Google Scholar]
  23. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  24. Morin C., Mitchell G., Larochelle J., Lambert M., Ogier H., Robinson B. H., De Braekeleer M. Clinical, metabolic, and genetic aspects of cytochrome C oxidase deficiency in Saguenay-Lac-Saint-Jean. Am J Hum Genet. 1993 Aug;53(2):488–496. [PMC free article] [PubMed] [Google Scholar]
  25. Narod S. A., Ford D., Devilee P., Barkardottir R. B., Lynch H. T., Smith S. A., Ponder B. A., Weber B. L., Garber J. E., Birch J. M. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):254–264. [PMC free article] [PubMed] [Google Scholar]
  26. Neuhausen S. L., Mazoyer S., Friedman L., Stratton M., Offit K., Caligo A., Tomlinson G., Cannon-Albright L., Bishop T., Kelsell D. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet. 1996 Feb;58(2):271–280. [PMC free article] [PubMed] [Google Scholar]
  27. Neuhausen S., Gilewski T., Norton L., Tran T., McGuire P., Swensen J., Hampel H., Borgen P., Brown K., Skolnick M. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996 May;13(1):126–128. doi: 10.1038/ng0596-126. [DOI] [PubMed] [Google Scholar]
  28. Oddoux C., Struewing J. P., Clayton C. M., Neuhausen S., Brody L. C., Kaback M., Haas B., Norton L., Borgen P., Jhanwar S. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996 Oct;14(2):188–190. doi: 10.1038/ng1096-188. [DOI] [PubMed] [Google Scholar]
  29. Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1041–1049. [PMC free article] [PubMed] [Google Scholar]
  30. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May;13(1):120–122. doi: 10.1038/ng0596-120. [DOI] [PubMed] [Google Scholar]
  31. Podratz K. C., Podczaski E. S., Gaffey T. A., O'Brien P. C., Schray M. F., Malkasian G. D., Jr Primary carcinoma of the fallopian tube. Am J Obstet Gynecol. 1986 Jun;154(6):1319–1326. doi: 10.1016/0002-9378(86)90719-2. [DOI] [PubMed] [Google Scholar]
  32. Ramus S. J., Kote-Jarai Z., Friedman L. S., van der Looij M., Gayther S. A., Csokay B., Ponder B. A., Olah E. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet. 1997 May;60(5):1242–1246. [PMC free article] [PubMed] [Google Scholar]
  33. Roa B. B., Boyd A. A., Volcik K., Richards C. S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996 Oct;14(2):185–187. doi: 10.1038/ng1096-185. [DOI] [PubMed] [Google Scholar]
  34. Rozen R., De Braekeleer M., Daigneault J., Ferreira-Rajabi L., Gerdes M., Lamoureux L., Aubin G., Simard F., Fujiwara T. M., Morgan K. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. Am J Med Genet. 1992 Feb 1;42(3):360–364. doi: 10.1002/ajmg.1320420322. [DOI] [PubMed] [Google Scholar]
  35. Schubert E. L., Lee M. K., Mefford H. C., Argonza R. H., Morrow J. E., Hull J., Dann J. L., King M. C. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet. 1997 May;60(5):1031–1040. [PMC free article] [PubMed] [Google Scholar]
  36. Serova-Sinilnikova O. M., Boutrand L., Stoppa-Lyonnet D., Bressac-de-Paillerets B., Dubois V., Lasset C., Janin N., Bignon Y. J., Longy M., Maugard C. BRCA2 mutations in hereditary breast and ovarian cancer in France. Am J Hum Genet. 1997 May;60(5):1236–1239. [PMC free article] [PubMed] [Google Scholar]
  37. Serova O., Montagna M., Torchard D., Narod S. A., Tonin P., Sylla B., Lynch H. T., Feunteun J., Lenoir G. M. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet. 1996 Jan;58(1):42–51. [PMC free article] [PubMed] [Google Scholar]
  38. Shattuck-Eidens D., McClure M., Simard J., Labrie F., Narod S., Couch F., Hoskins K., Weber B., Castilla L., Erdos M. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA. 1995 Feb 15;273(7):535–541. [PubMed] [Google Scholar]
  39. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., Pruss D., Tavtigian S. V., Teng D. H., Adey N. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997 Oct 15;278(15):1242–1250. [PubMed] [Google Scholar]
  40. Simard J., Tonin P., Durocher F., Morgan K., Rommens J., Gingras S., Samson C., Leblanc J. F., Bélanger C., Dion F. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 1994 Dec;8(4):392–398. doi: 10.1038/ng1294-392. [DOI] [PubMed] [Google Scholar]
  41. Stajich J. M., Gilchrist J. M., Lennon F., Lee A., Yamaoka L., Helms B., Gaskell P. C., Donald L., Roses A. D., Vance J. M. Confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13. Ann Neurol. 1996 Nov;40(5):801–804. doi: 10.1002/ana.410400519. [DOI] [PubMed] [Google Scholar]
  42. Stoppa-Lyonnet D., Laurent-Puig P., Essioux L., Pagès S., Ithier G., Ligot L., Fourquet A., Salmon R. J., Clough K. B., Pouillart P. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet. 1997 May;60(5):1021–1030. [PMC free article] [PubMed] [Google Scholar]
  43. Stratton J. F., Gayther S. A., Russell P., Dearden J., Gore M., Blake P., Easton D., Ponder B. A. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997 Apr 17;336(16):1125–1130. doi: 10.1056/NEJM199704173361602. [DOI] [PubMed] [Google Scholar]
  44. Struewing J. P., Abeliovich D., Peretz T., Avishai N., Kaback M. M., Collins F. S., Brody L. C. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995 Oct;11(2):198–200. doi: 10.1038/ng1095-198. [DOI] [PubMed] [Google Scholar]
  45. Struewing J. P., Brody L. C., Erdos M. R., Kase R. G., Giambarresi T. R., Smith S. A., Collins F. S., Tucker M. A. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet. 1995 Jul;57(1):1–7. [PMC free article] [PubMed] [Google Scholar]
  46. Szabo C. I., King M. C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997 May;60(5):1013–1020. [PMC free article] [PubMed] [Google Scholar]
  47. Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333–337. doi: 10.1038/ng0396-333. [DOI] [PubMed] [Google Scholar]
  48. Tonin P., Serova O., Lenoir G., Lynch H., Durocher F., Simard J., Morgan K., Narod S. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet. 1995 Jul;57(1):189–189. [PMC free article] [PubMed] [Google Scholar]
  49. Tonin P., Weber B., Offit K., Couch F., Rebbeck T. R., Neuhausen S., Godwin A. K., Daly M., Wagner-Costalos J., Berman D. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov;2(11):1179–1183. doi: 10.1038/nm1196-1179. [DOI] [PubMed] [Google Scholar]
  50. Vehmanen P., Friedman L. S., Eerola H., Sarantaus L., Pyrhönen S., Ponder B. A., Muhonen T., Nevanlinna H. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet. 1997 May;60(5):1050–1058. [PMC free article] [PubMed] [Google Scholar]
  51. Wagner T. M., Möslinger R., Zielinski C., Scheiner O., Breiteneder H. New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families. Lancet. 1996 May 4;347(9010):1263–1263. doi: 10.1016/s0140-6736(96)90781-3. [DOI] [PubMed] [Google Scholar]
  52. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES